Linked Life Data

319895

Source:http://linkedlifedata.com/resource/pubmed/id/319895

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1977-4-25
pubmed:abstractText
One hundred and ten Group III patients enrolled in the IRS Study have been reviewed. Of these, 39 are fully and 56 are partially evaluable. Combining the data for both groups 77/95 (81%) have shown complete or partial response/no measurable disease and this has been maintained in 53/95 (56%). No patient received premature RT for local progression during the time of pre-radiation chemotherapy. However, 15/95 patients have shown local recurrence or direct extension to neighboring tissues; 13/15 could be reviewed. Only 3/13 have recurred at a time related to the delay in starting radiation. Overall survival for Group III patients is 72%-85% (Regimen F and Regimen E respectively).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0008-543X
pubmed:author
pubmed:issnType
Print
pubmed:volume
39
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
665-70
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1977
pubmed:articleTitle
Rhabdomyosarcoma: response with chemotherapy prior to radiation in patients with gross residual disease.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Research Support, U.S. Gov't, P.H.S.